Biological Psychiatry
September 15, 2023
Robin J Murphy, Rachael Sumner, William Evans et al.
69 citations
Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity. Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups...
CNS Drugs
September 1, 2023
Antonio Inserra, Alexandre Piot, Danilo de Gregorio et al.
17 citations
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global economic burden. Over 50% of individuals with ADs do not respond to standard therapies, making the identification of more effective anxiolytic drugs an ongoing research priority. In this work, we review the preclinical literature concerning the effects of lysergic acid...
Journal of Applied Toxicology
August 30, 2023
Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al.
2 citations
Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...
Journal of Psychoactive Drugs
August 24, 2023
Stanley Wong, An Yi Yu, Nicholas Fabiano et al.
11 citations
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...
Journal of Psychedelic Studies
August 21, 2023
Benjamin M. Ross, James T. Neill
6 citations
Abstract Background Psilocybin, the psychoactive compound in magic mushrooms, is increasingly discussed in terms of its psychotherapeutic potential; however, little is known about community attitudes towards psilocybin assisted therapy (PAT). Aims To address the question: What are the public's attitudes towards psilocybin and psilocybin-assisted therapy? And what factors explain these...
Research Square (Research Square)
July 7, 2023
Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al.
4 citations
preprint
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in...
Current Topics in Medicinal Chemistry
July 6, 2023
Udoka C. Ezeaka, Hye Ji J. Kim, Robert B. Laprairie
1 citation
Abstract: Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will summarize the evidence...
June 9, 2023
Mika Turkia
2 citations
preprint
This retrospective study presents the case of a young woman in her mid-twenties who suffered from insecurity and abandonment-related anxiety, which intensified after a breakup of her relationship. Her parents' alcoholism and schizophrenia, as well as emotional and physical violence, had been a part of her childhood, but they had appeared 'normal' to her. Her parents and relatives had not...
Folia Pharmacologica Japonica
March 28, 2023
Daisuke Ibi
1 citation
Major depressive disorder presents a substantial global health burden, and at least 30-40% of patients exhibit treatment resistance to antidepressants. Ketamine, an NMDA receptor antagonist, is used as an anesthetic agent. In 2019, the U.S. Food and Drug Administration (FDA) approved esketamine (the S-enantiomer of ketamine) as a therapeutic agent for treatment-resistant depression; however,...
March 10, 2023
Mika Turkia
4 citations
preprint
In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a reversal of that concept is proposed: psychedelics could be conceptualized as a tool for people chronically anxious and depressed since early childhood to understand ordinary states of mind (e.g. calmness, hopefulness, relaxation, and joy). The case...